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a  b  s  t  r  a  c  t
Selective  estrogen  receptor  modulators  (SERMs)  demonstrate  differential  endometrial  cancer  (EC)  risk.
While  tamoxifen  (TAM)  use  increases  the  risk  of endometrial  hyperplasia  and  malignancy,  raloxifene
(RAL)  has  neutral  effects  on the  uterus.  How  TAM  increases  the  risk  of  EC  and  why  TAM  and  RAL  dif-
ferentially  modulate  the risk  for EC,  however,  remain  elusive.  Here,  we  tested  the  hypothesis  that  TAM
increases  the  risk  for EC,  at  least  in  part,  by enhancing  the  local  estrogen  biosynthesis  and  directing
estrogen  metabolism  towards  the  formation  of  genotoxic  and  hormonally  active  estrogen  metabolites.
In  addition,  the  differential  effects  of  TAM  and  RAL  in EC  risk  are  attributed  to  their  differential  effect
on  estrogen  metabolism/metabolites.  The  endometrial  cancer  cell  line  (Ishikawa  cells)  and  the non-
malignant  immortalized  human  endometrial  glandular  cell  line  (EM1)  were  used  for  the  study.  The
profile  of  estrogen/estrogen  metabolites  (EM),  depurinating  estrogen-DNA  adducts,  and  the  expression
of estrogen-metabolizing  enzymes  in  cells  treated  with  17-estradiol  (E2)  alone  or in combination  with
TAM or  RAL  were  investigated  using  high  performance  liquid  chromatography–electrospray  ionization-
tandem  mass  spectrometry  (HPLC–ESI-MS2),  ultraperformance  liquid  chromatography/tandem  mass
spectrometry  (UPLC–MS/MS),  and  Western  blot  analysis,  respectively.  TAM  significantly  increased  the
total EM  and  enhanced  the formation  of hormonally  active  and  carcinogenic  estrogen  metabolites,
4-hydroxestrone  (4-OHE1)  and  16-hydroxyestrone,  with  concomitant  reduction  in  the  formation  of
antiestrogenic  and  anticarcinogenic  2-hydroxyestradiol  and  2-methoxyestradiol.  Furthermore,  TAM
increased  the  formation  of  depurinating  estrogen-DNA  adducts  4-OHE1  [2]-1-N7Guanine  and  4-OHE1
[2]-1-N3  Adenine.  TAM-induced  alteration  in  EM  and  depurinating  DNA  adduct  formation  is associated
with  altered  expression  of  estrogen  metabolizing  enzymes  CYP1A1,  CYP1B1,  COMT,  NQO1,  and  SF-1 as
revealed  by  Western  blot  analysis.  In contrast  to TAM,  RAL  has  minimal  effect  on EM, estrogen-DNA
adduct  formation,  or estrogen-metabolizing  enzymes  expression.  These  data  show  that  TAM  perturbs
the balance  of estrogen-metabolizing  enzymes  and  alters  the  disposition  of  estrogen  metabolites,  which
can  explain,  at  least  in  part,  the  mechanism  for TAM-induced  EC.  These  results  also  implicate  the  dif-
ferential  effect  of  TAM  and  RAL  on estrogen  metabolism/metabolites  as  a  potential  mechanism  for  their
disparate  effects  on the  endometrium.
© 2011 Elsevier Ltd. All rights reserved.
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1. Introduction
Tamoxifen (TAM), the first selective estrogen receptor modula-
tor (SERM) available for clinical use, is regarded as a highly effective
agent for the prevention and treatment of breast cancer. How-
ever, the long-term use of TAM is associated with endometrial
thickening, dysfunctional uterine bleeding, endometrial polyps,
endometrial hyperplasia, and endometrial cancer [1–3]. By con-
trast, raloxifene (RAL), another member of the SERM class of drugs,
currently approved for the prevention and treatment of post-
menopausal osteoporosis and for the prevention of breast cancer,
seems to have neutral effects on endometrium [4].  Although, both
TAM and RAL apparently have a similar mechanism of action,
the molecular mechanism underlying their different effects on
endometrium and the mechanism whereby TAM imposes increased
risk for EC are not clear. Understanding the relevant pathways
involved in TAM-associated EC is a matter of great importance to
allow more accurate assessment of the risk to women receiving
TAM treatment or, more importantly, to develop chemoprevention
approaches. Several attempts have been made to understand the
mechanism of TAM-associated EC. Nevertheless, there are linger-
ing controversies surrounding the proposed mechanisms, and the
resulting data is not conclusive. It has been postulated that the asso-
ciation of TAM with EC is attributed to certain TAM metabolites,
which are able to bind to DNA to form adducts and cause DNA dam-
age [5–9]. However, analysis of TAM-DNA adducts in endometrial
tissues from women treated with TAM has yielded mixed results
[10]. Even though TAM-DNA adduct formation is possible in human
tissues, it may  only occur in a proportion of patients, and in such
cases, the levels are likely to be very low; therefore, proving a causal
link between the presence of specific TAM-DNA adducts and the
development of EC is extremely difficult. Thus, whether TAM-DNA
adducts contribute to the development of EC depends on whether
they can actually be formed in endometrial tissues and on the type
of specific molecular and cellular responses they induce, if present.
Indeed, it has been reported that TAM-DNA adducts are formed
in immortalized human hepatocytes but not in human endome-
trial carcinoma cells, suggesting that TAM-DNA adduct formation
may  not be an absolute requirement for the development of EC
[11,12]. In addition, several investigators found no evidence for the
presence of TAM-DNA adducts in endometrial DNA from women
who had undergone TAM therapy for extended period of time,
even by using the more sensitive and specific HPLC–electrospray
ionization-tandem mass spectrometry (HPLC–ESI-MS/MS) assay
[13–17].  This apparent inconsistency in the data suggests that
although TAM-adduct formation may  occur at a very low level
in a proportion of patients, an alternative/complementary mech-
anism underlying TAM-induced EC may  also be a factor. Plausible
evidence suggests that the effect of TAM on the endometrium
is mediated, at least in part, by modulating estrogen biosynthe-
sis and metabolism. First, several reports indicate that aromatase
inhibitors prevent endometrial growth and reverse TAM-induced
uterine changes in postmenopausal breast cancer patients [18,19].
Secondly, molecular genetic studies indicate that genetic alter-
ations associated with Type I endometrial carcinomas—commonly
associated with TAM use—include mutations in PTEN, K-RAS, and
the formation of microsatellite instabilities [20]. These alterations
have been found to be induced by certain estrogen metabolites
in human endometrial glandular epithelial cells [21]. In addition,
mounting evidence suggests that TAM modulates gene expres-
sion of estrogen biosynthesis and metabolism. For instance, it
has been reported that TAM increases SF-1 transcription and
induces the SF-1 target gene aromatase expression, regulates the
activities of 17 beta-hydroxysteroid dehydrogenase activity and
NAD(P)H: quinone oxidoreductase (NQO1), and increases the 16
alpha-hydroxylation of estrogen [22–27].  Thus, these notions led
us to hypothesize that TAM increases the risk for EC, at least
in part, by enhancing the local estrogen biosynthesis and direct-
ing estrogen metabolism towards the formation of genotoxic and
hormonally active estrogen metabolites. We also propose that dif-
ferential effects of TAM and RAL in EC risk can be explained by their
differential effects on estrogen metabolism/metabolites. This is a
novel approach as the mainstream focus of study regarding TAM-
associated endometrial cancer has been on the effects of TAM on
DNA or the effects of estrogen on endometrial tissues. Our approach
specifically investigates the effect of TAM on estrogen metabolism,
and we  propose that this relationship directly contributes to the
increased risk of endometrial cancer.
2. Materials and methods
2.1. Cells and cell culture
Immortalized nonmalignant human endometrial glandular cell
line (EM1), which express both estrogen and progesterone recep-
tors and retain the function and characteristic of the primary
cells, were a gift from Dr. Satoru Kyo (Department of Obstet-
rics and Gynecology, Kanazawa University School of Medicine,
Kanazawa, Japan) [28]. The endometrial cancer cell line, Ishikawa,
was  obtained from the American Type Culture Collections (ATCC,
Manassas, VA). EM1  and Ishikawa cells were maintained in 5%
CO2/air in Dulbecco’s minimal essential medium (DMEM), free of
serum and phenol red and supplemented with 10% fetal bovine
serum and 1% antibiotic–antimycotic solution. Forty-eight hours
before the treatment, the cells were weaned in serum-free media.
Then, the cells were treated with E2 (10 nM)  alone or in com-
bination with increasing concentrations (100 nM to 10 M) of
either 4-hydroxytamoxifen (4OH-TAM), which is the active form of
tamoxifen, or RAL. Forty-eight hours later, the media were collected
and stored at −80 ◦C until used for the analysis of estrogen metabo-
lites and estrogen-DNA adducts. We  also collected the treated cells
for RNA and protein extraction.
2.2. Determination of estrogen/estrogen metabolites in the
growth media
The levels of estrogen and estrogen metabolites (EM) were
determined by testing the conditioned media from cells treated
with E2 and/or different doses of 4OH-TAM or RAL according to
the methods described by Xu et al. [29]. Briefly, 5 L of the stable
isotope labeled estrogen and estrogen metabolite (SI-EM) working
internal standard solution (40 pg SI-EM) was  added to 400 L cell
medium aliquot followed by 500 L of 0.15 M sodium acetate buffer
(pH 4.6) containing 0.25% (w/v) l-ascorbic acid. Dichloromethane
(6 mL)  was  added to the sample, which then underwent inverse
extraction at 8 rpm (RKVSDTM, ATR, Inc., Laurel, MD)  for 30 min.
After extraction, the aqueous layer was  discarded, and the organic
solvent portion was transferred into a clean glass tube and evapo-
rated to dryness under a stream of nitrogen gas at 60 ◦C (Reacti-Vap
IIITM, Pierce, Rockford, IL). The dried sample residue was  then redis-
solved in 40 L of 0.1 M sodium bicarbonate buffer (pH 9.0) and
40 L of dansyl chloride solution (1 mg/mL  in acetone). After soni-
cation, the sample was heated at 60 ◦C (Reacti-Therm IIITM Heating
Module, Pierce, Rockford, IL) for 5 min  to form the EM and SI-
EM dansyl derivatives (EM-dansyl and SI-EM-dansyl), respectively.
After derivatization, all samples were analyzed using high per-
formance liquid chromatography–electrospray ionization-tandem
mass spectrometry (HPLC–ESI-MS2). Capillary HPLC–ESI-MS2 anal-
ysis was  performed using an Agilent 1200 series nanoflow LC
system (Agilent Technologies, Palo Alto, CA) coupled to a TSQTM
Quantum Ultra triple quadrupole mass spectrometer (Thermo
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Electron, San Jose, CA). Quantitation of cell medium estrogen
metabolites was carried out using XcaliburTM Quan Browser
(Thermo Electron) as previously described [29]. According to
this method, we were capable of quantifying simultaneously
15 estrogens and estrogen metabolites: estrone and its 2-, 4-,
and 16-alpha-hydroxy and 2- and 4-methoxy derivatives; 2-
hydroxyestrone-3-methyl ether; 17beta-E2 and its 2-hydroxy
and 2- and 4-methoxy derivatives; and estriol, 17-epiestriol, 16-
ketoestradiol, and 16-epiestriol. This experiment was  done in
collaboration with Dr. Timothy Veenestra (NCI, Frederick, MD).
2.3. HPLC analysis of estrogen-induced depurinating DNA adducts
The EM1  and Ishikawa cells were treated as described above.
The growth medium was used to measure the level of depurinat-
ing estrogen-DNA adducts according to the method described by
Zahid et al. [30]. Briefly, cell culture medium was extracted by using
Varian C8 Certify II solid phase extraction cartridge (Varian, Harbor
City, CA). The cartridges were preequilibrated by sequentially pass-
ing 1 mL  methanol, distilled water, and potassium phosphate buffer
(100 mM,  pH 8.0) through them. Culture medium was  adjusted with
1 mL  of 1 M potassium phosphate to pH 8 and passed through the
cartridge. After washing with 2 mL  of 100 mM potassium phosphate
and 5 mL  of distilled water, the analytes were eluted with 1 mL
of elution buffer comprised of methanol/acetonitrile/water/TFA
(8:1:1:0.1). The eluent was  evaporated to about 100 L by using a
Jouan RC10 Vacuum Concentrator and reconstituted with 100 L of
MeOH/water (1:1). The solution was then passed through 5000 MW
cut off filters and analyzed on HPLC connected with multiple elec-
trochemical detectors.
2.4. HPLC analysis of adducts
Analyses of all samples were conducted on an HPLC sys-
tem equipped with a dual ESA Model 580 autosampler,
and a 12-channel CoulArray electrochemical detector (ESA,
Chelmsford, MA). The 2 mobile phases used were (A) ace-
tonitrile/methanol/buffer/water (15:5:10:70) and (B) acetoni-
trile/methanol/buffer/water (50:20:10:20). The buffer was a
mixture of 0.25 M citric acid and 0.5 M ammonium acetate in triple-
distilled water, and the pH was adjusted to 3.6 with acetic acid.
The 95 L injections were carried out on a Phenomenex Luna-
2C–18column (250 mm × 4.6 mm  ID, 5 mm;  Phenomenex, Torrance,
CA), initially eluted isocartically at 90% A/10% B for 15 min, followed
by a linear gradient to 90% B/10% A in the next 40 min, and held
there for 5 min  (total 50 min  gradient) at a flow rate of 1 mL/min
and a temperature of 30 ◦C. The serial array of 12 coulometric elec-
trodes was set at potentials of −35, 10, 70, 140, 210, 280, 350, 420,
490, 550, 620, and 690 mV.  The system was controlled, and the data
were acquired and processed using the CoulArray software package
(ESA). Peaks were identified by both retention time and peak height
ratios between the dominant peaks and the peaks in the 2 adjacent
channels. The metabolites, conjugates, and depurinating adducts
were quantified by comparison of peak response ratios with known
amounts of standards. The level of adducts were normalized against
cell numbers and the DNA contents.
2.5. Western blot analysis
EM-1 and Ishikawa were treated with E2 alone or in combination
with increasing concentrations of 4OH-TAM and RAL as previously
described. And after 72 h, the cells were washed with phosphate-
buffered saline (PBS), and whole cell lysates were prepared with
RIPA lysis buffer. The cell lysates were solubilized in sample
buffer (60 mM Tris–hydrochloride [HCl], pH 6.8; 2% sodium dode-
cyl sulfate [SDS]; 10% glycerol; 0.7 mol/L 2--mercaptoethanol;
0.01% bromophenol blue) and subjected to SDS-polyacrylamide gel
electrophoresis (PAGE). Proteins were electroblotted onto nitro-
cellulose membranes. Membranes were immunoblotted with the
primary antibody against COMT, NQO1, CYP1A1, CYP1B1, or -
actin. After washing, membranes were incubated with horseradish
peroxidase (HRP)-conjugated secondary antibodies (Vector Labo-
ratories, Burlingame, CA). The intensity of each protein band was
determined using a scanning densitometer (Epson 4870, Epson
America, Long Beach, CA).
2.6. Statistical analyses
Absolute concentrations of individual estrogen metabolites
(EM) were normalized against protein concentrations and
expressed as picomoles per microgram protein per 48 h. As
previously described by Eliassen, individual EM were com-
bined according to chemical characteristics (e.g., catechols and
methylated catechols) and pathways (e.g., 2-hydroxylation, 4-
hydroxylation, and 16-hydroxylation pathways), and absolute
concentrations of these EM groups were calculated by summing the
individual EM in the group [31]. Total estrogen metabolites were
calculated as the sum of each of the 15 EM.  Percents of EM were
obtained by dividing the individual or grouped EM by the total EM.
Ratios of selected EM groups also were calculated. Although, we  did
not assess most ratios of individual EM,  we evaluated the certain
ratios, which are considered potential predictors of endometrial
cancer risk. Statistical analyses were conducted using SAS v. 9.1
(SAS Institute, Cary, NC). Data are presented as the mean ± standard
error of the mean (M ± SEM) for each experiment. Absolute levels
of each EM were expressed in picomoles per milligram protein.
Relative EM levels (% EMet) were expressed as a percentage of
total EM.  Statistical significance between different treatments was
determined by 1-way analysis of variance (ANOVA) followed by
post hoc comparison using Student t-test.
3. Results
3.1. Total EM in endometrial cells treated with E2 with or without
TAM or RAL
To evaluate the effects of TAM or RAL on estrogen metabolism,
the sum of the absolute levels of total EM was  measured in condi-
tioned media from EM1  and Ishikawa cells treated with E2 (10 nM)
alone or in combination with different concentrations (100 nM or
1 M)  of TAM or RAL. As indicated in Table 1, the total estrogens
and estrogen metabolites were significantly higher in the media
from EM1  cells treated with E2 (10 nM)  plus TAM (100 nM or 1 M)
compared with cells treated with E2 (10 nM)  alone. In contrast,
treatment with RAL did not significantly affect the total EM com-
pared with cells treated with E2 alone (Table 1). Likewise, a similar
profile of EM was  obtained from Ishikawa cells under similar treat-
ment conditions (Table 2).
3.2. Profile of specific EM in endometrial cells treated with E2
with or without TAM or RAL
We  assessed the effect of TAM or RAL on the level of certain
estrogen metabolites in conditioned media with unique and known
roles in estrogen-induced EC. The estrogen metabolite 2-OHE2 has
weak estrogenic or even antiestrogenic effects and, therefore, influ-
ences the hormonal and carcinogenic effects of estrogen. Thus,
we assessed the rate of 2-OHE2 formation in cells treated with
E2 alone or in combination with TAM or RAL. Our data indicated
that 2-OHE2 is one of the major EM detected in conditioned media
from EM1  and Ishikawa cells. As illustrated in Table 1, in EM1  cells
treated with E2 alone, the rate of 2-OHE2 formation was 3.7 ± 0.4%
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Table  1
Effect of TAM or RAL on total EM in EM1  cells. The rate and profile of total estrogen/estrogen metabolites in culture media from EM1  cells treated with E2 10 nM alone or
with  various concentrations of TAM or RAL. Cells were grown in serum-free media and treated for 48 h. Media were collected to quantify total EM by HPLC–electrospray
ionization-tandem mass spectrometry. Data were normalized against protein concentration.
Mean pmole/mg protein/48 h (% from the total)
E2 alone (10 nM) E2  + TAM (100 nM) E2 + TAM (1 M)  E2 + RAL (100 nM) E2 + RAL (1 M)
Parent estrogens
Estrone (E1) 530 ± 60 340 ± 20 310 ± 80 590 ± 40 420 ± 30
(12 ± 3) (7 ± 1) (6 ± 3) (15 ± 4) (10 ± 7)
Estradiol (E2) 3500 ± 100 4690 ± 70 5200 ± 300 3000 ± 100 3900 ± 300
(83  ± 1) (91.4 ± 0.4) (93 ± 1) (80 ± 1) (87.1 ± 0.6)
2-Hydroxylation pathway EM catechols
2-Hydroxyestrone (2-OHE1) 1.760 ± 0.007 0.94 ± 0.11* 1.05 ± 0.05* 1.84 ± 0.04 1.92 ± 0.08
2-Hydroxyestradiol (2-OHE2) 157 ± 17 90 ± 8* 75 ± 1* 147 ± 3 138 ± 7
(3.7 ± 0.4) (1.80 ± 0.02) (1.30 ± 0.02) (3.90 ± 0.09) (3.10 ± 0.02)
Methylated catechols
2-Methoxyestrone (2-MeOE1) 0.040 ± 0.001 0.025 ± 0.001 0.030 ± 0.004 0.030 ± 0.005 0.030 ± 0.002
2-Methoxyestradiol (2-MeOE2) 3.7 ± 0.5 2.23 ± 0.08 2.0 ± 0.5 3.9 ± 0.3 3.9 ± 0.1
(0.09  ± 0.01) (0.040 ± 0.001) (0.04 ± 0.01) (0.10 ± 0.01) (0.090 ± 0.001)
2-Hydroxyestrone-3-methyl ether (3-MeOE1) 0.007 ± 0.002 0.004 ± 0.001 0.004 ± 0.001 0.004 ± 0.002 0.003 ± 0.001
4-Hydroxylation pathway EM catechols
4-Hydroxyestrone (4-OHE1) 2.53 ± 0.06 3.59 ± 0.16* 3.7 ± 0.5* 2.03 ± 0.04 1.81 ± 0.13
Methylated catechols
4-Methoxyestrone (4-MeOE1) 0.09 ± 0.02 0.040 ± 0.006 0.040 ± 0.008 0.070 ± 0.008 0.080 ± 0.003
4-Methoxyestradiol (4-MeOE2) 0.36 ± 0.07 0.200 ± 0.008 0.190 ± 0.006 0.260 ± 0.006 0.26 ± 0.01
16-Hydroxylation pathway EM
16-Hydroxyestrone (16-OHE1) 0.32 ± 0.02 0.58 ± 0.02 0.65 ± 0.08 0.24 ± 0.04 0.21 ± 0.04
Estriol  (E3) 7 ± 1 3.8 ± 0.3 6 ± 1 4.4 ± 0.3 4.3 ± 0.4
(0.20  ± 0.03) (0.100 ± 0.001) (0.10 ± 0.01) (0.10 ± 0.01) (0.090 ± 0.001)
17-Epiestriol (17-epiE3) 0.040 ± 0.006 0.020 ± 0.002 0.030 ± 0.004 0.030 ± 0.002 0.030 ± 0.005
16-Ketoestradiol (16-ketoE2) 0.29 ± 0.03 0.15 ± 0.01 0.24 ± 0.04 0.17 ± 0.01 0.17 ± 0.02
16-Epiestriol (16-epiE3) 0.59 ± 0.09 0.38 ± 0.02 0.50 ± 0.07 0.78 ± 0.09 0.73 ± 0.03
Total  EM (M ± SEM) 4200 ± 200 5130 ± 90* 5600 ± 200* 3800 ± 200 4400 ± 300
*Significant (P < 0.05) difference compared with treatment with E2 alone. Values represent the mean (standard error of the mean) of three independent experiments.
Table 2
Effect of TAM or RAL on total EM in Ishikawa cells. The rate and profile of total estrogen/estrogen metabolites in culture media from Ishikawa cells treated with E2 10 nM alone
or  with various concentrations of TAM or RAL. Cells were grown in serum-free media and treated for 48 h. Media were collected to quantify total EM by HPLC–electrospray
ionization-tandem mass spectrometry. Data were normalized against protein concentration.
Mean pmole/mg protein/48 h (% from the total)
E2 alone (10 nM)  E2 + TAM (100 nM)  E2 + TAM (1 M)  E2 + RAL (100 nM) E2 + RAL (1 M)
Parent estrogens
Estrone (E1) 870 ± 30 800 ± 100 900 ± 100 900 ± 100 1000 ± 200
(15.5 ± 0.5) (11 ± 2) (12 ± 2) (17 ± 3) (19 ± 4)
Estradiol (E2) 4600 ± 200 6700 ± 400 6900 ± 200 4500 ± 200 4100 ± 100
(83  ± 4) (89 ± 3) (88 ± 3) (81 ± 4) (80 ± 4)
2-Hydroxylation pathway EM catechols
2-Hydroxyestrone (2-OHE1) 1.0 ± 0.2 0.79 ± 0.05 0.61 ± 0.08 2 ± 1 0.86 ± 0.09
2-Hydroxyestradiol (2-OHE2) 46 ± 1 39 ± 4 34 ± 3 50 ± 20 44 ± 4
(0.83 ± 0.02) (0.50 ± 0.05) (0.43 ± 0.04) (2.3 ± 0.3) (0.85 ± 0.07)
Methylated catechols
2-Methoxyestrone (2-MeOE1) 0.006 ± 0.002 0.015 ± 0.003 0.008 ± 0.008 0.05 ± 0.02 0.006 ± 0.002
2-Methoxyestradiol (2-MeOE2) 10.0 ± 0.8 5.3 ± 0.8 4.1 ± 0.5 8.7 ± 0.9 11.1 ± 0.4
(0.18  ± 0.02) (0.07 ± 0.01) (0.050 ± 0.006) (0.16 ± 0.02) (0.200 ± 0.006)
2-Hydroxyestrone-3-methyl ether (3-MeOE1) 0.0007 ± 0.0001 0.0012 ± 0.0003 0.001 ± 0.001 0.009 ± 0.006 0.003 ± 0.008
4-Hydroxylation pathway EM catechols
4-Hydroxyestrone (4-OHE1) 1.0 ± 0.3 2.3 ± 0.3 9 ± 1 1.1 ± 0.1 1.22 ± 0.01
Methylated catechols
4-Methoxyestrone (4-MeOE1) 0.11 ± 0.03 0.07 ± 0.01 0.08 ± 0.01 0.29 ± 0.09 0.17 ± 0.03
4-Methoxyestradiol (4-MeOE2) 0.28 ± 0.01 0.18 ± 0.01 0.140 ± 0.002 0.290 ± 0.004 0.310 ± 0.002
16-Hydroxylation pathway EM
16-Hydroxyestrone (16-OHE1) 0.17 ± 0.02 0.32 ± 0.03 0.288 ± 0.002 0.17 ± 0.01 0.19 ± 0.04
Estriol  (E3) 1.38 ± 0.02 1.461 ± 0.006 1.743 ± 0.002 4.7 ± 2.2 1.917 ± 0.002
(0.0250 ± 0.0003) (0.0220 ± 0.0001) (0.02300 ± 0.00001) (0.08 ± 0.04) (0.03700 ± 0.00003)
17-Epiestriol (17-epiE3) 0.027 ± 0.007 0.037 ± 0.006 0.027 ± 0.004 0.08 ± 0.03 0.024 ± 0.003
16-Ketoestradiol (16-ketoE2) 0.142 ± 0.005 0.24 ± 0.03 0.24 ± 0.03 0.5 ± 0.2 0.19 ± 0.04
16-Epiestriol (16-epiE3) 0.25 ± 0.02 0.35 ± 0.05 0.38 ± 0.01 0.8 ± 0.3 0.30 ± 0.06
Total  EM (M ± SEM) 5600 ± 200 7700 ± 400 7900 ± 300* 5600 ± 400 5200 ± 400
*Significant (P < 0.05) difference compared with treatment with E2 alone. Values represent the mean (standard error of the mean) of three independent experiments.
of total EM.  However, treatment with TAM (100 nM or 1 M)  signif-
icantly decreased the rate of 2-OHE2 formation to 1.8 ± 0.02% and
1.3 ± 0.02% of total EM,  respectively. In contrast, in EM cells treated
with E2 and 100 or 1 M of RAL, there were no significant changes
in the rate of 2-OHE2 formation (3.9 ± 0.09% and 3.1 ± 0.017% of
total EM,  respectively). Our data also suggested that Ishikawa cells
metabolize E2 into 2-OHE2 at a lower rate (<1% of total EM)  in com-
parison to EM1  cells. However, TAM exhibited a subtle decrease on
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Fig. 1. The E1/E2 ratio was significantly lower compared with cells treated with
E2  alone in EM1  cells treated with E2 plus TAM. The ratio of E1/E2 ratio in culture
media from EM1  cells treated with E2 10 nM alone or with various concentrations
of  TAM or RAL. Cells were grown in serum-free media and treated for 48 h. Media
were collected to quantify the E1/E2 ratio by HPLC–electrospray ionization-tandem
mass spectrometry. Data were normalized against protein concentration. *Signifi-
cant (P < 0.05) difference compared with treatment with E2 alone. Values represent
the  mean; bars represent the standard error of the mean.
the formation rate of 2-OHE2, while RAL tended to increase the for-
mation rate of 2-OHE2 significantly at the 100 nM concentration,
compared with Ishikawa cells treated with E2 alone (Table 2).
The rate of 2-OHE1 formation was lower compared with
the formation rate of 2-OHE2 in both EM1  and Ishikawa cells
(Tables 1 and 2). Our data confirmed that in EM1  cells, TAM sig-
nificantly reduced the rate of 2-OHE1 formation compared to cells
treated with E2 alone, while RAL had no significant effect (Table 1).
16-Hydroxyestrone (16-OHE1) has strong hormonal and
tumor-promoting activities; thus, we assessed the rate of 16-
OHE1 in E2- and TAM-treated cells. Our data demonstrate that the
formation of 16-OHE1 was significantly higher in TAM-treated
cells compared to cells treated with E2 alone in both EM1  and
Ishikawa cells. In contrast to TAM, RAL did not induce significant
change in the rate of 16-OHE1 formation (Tables 1 and 2).
4-Hydroxyestrone is a tumor-promoting estrogen metabolite
that induces oxidative stress, microsatellite instability, and neo-
plastic transformation in EM1  cells. Therefore, we assessed the
effect of TAM or RAL on E2 metabolism into 4-OHE1. Our results
indicate that TAM significantly enhanced E2 metabolism into 4-
OHE1 in EM1  cells. However, RAL did not have a profound effect
on the formation rate of 4-OHE1 (Table 1). A comparable pattern
of TAM or RAL effects on 4-OHE1 formation rate was observed in
Ishikawa cells (Table 2).
The rate of formation of methoxyestrogens is critical for estro-
gen carcinogenesis. We  analyzed the effects of TAM or RAL on
the rate of methoxyestrogen formation. 2-methoxyestradiol (2-
MeOE2) is an anticancer and antiangiogenic agent. As illustrated
in Tables 1 and 2, 2-MeOE2 is the major methylated catechol estro-
gen detected and to a lesser extent, 4-methoxyestadiol (4-MeOE2),
4-methoxyestrone (4-MeOE1), and 2-methoxyestrone (2-MeOE1),
in decreasing rates. Compared with E2-treatment alone, TAM
markedly decreased the rate of methoxyestrogens formation, in
both EM1  and Ishikawa cells (Tables 1 and 2). On the other hand,
RAL did not change methoxyestrogens formation rates in either cell
line (Tables 1 and 2).
3.3. Effect of TAM or RAL on the ratios of specific estrogen
metabolites in endometrial cells
To further assess the effects of TAM and RAL on estrogen
metabolism, we  derived the ratios for E1/E2, 2-OHE1/16-OHE1,
and 2-MeOE2/4-OHE1, which are the most commonly used predic-
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E2  alone in Ishikawa cells treated with E2 plus TAM. The ratio of E1/E2 ratio in
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compared with treatment with E2 alone. Values represent the mean; bars represent
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Fig. 3. Treatment with E2 and TAM significantly decreased the 2-OHE1/16-OHE1
ratio compared with the treatment with E2 alone in EM1  cells; E2 and RAL increased
this  ratio. The ratio of 2-OHE1/16- OHE1 ratio in culture media from EM1  cells
treated with E2 10 nM alone or with various concentrations of TAM or RAL as previ-
ously described. *Significant (P < 0.05) difference compared with treatment with E2
alone. Values represent the mean; bars represent the standard error of the mean.
tors for cancer risk. As indicated in Fig. 1, TAM shifted the E1/E2
equilibrium towards the formation of more E2. Thus, in EM1  cells
treated with E2 plus TAM, the E1/E2 ratio was significantly lower
compared with cells treated with E2 alone. However, in cells treated
with E2 and RAL, the E1/E2 ratio increased compared with E2-only-
treated cells. Similarly, in Ishikawa cells, the profile of E1/E2 ratios
following treatment with TAM or RAL was comparable to that in
EM1  cells (Fig. 2).
Our data indicate that in EM1  and Ishikawa cells, treatment with
E2 and TAM significantly decreased the 2-OHE1/16-OHE1 ratio
compared with treatment with E2 alone, and, in contrast, E2 and
RAL increased this ratio (Figs. 3 and 4).
We evaluated the 2-MeOE2/4-OHE1 ratios resulting from treat-
ing endometrial cells with E2 alone or in combination with TAM or
RAL in EM1  and Ishikawa cells. Our data suggest that while treat-
ment with TAM significantly decreased the 2-MeOE2/4-OHE1 ratio
in both cell lines, treatment with RAL increased this ratio signifi-
cantly in EM1  cells (Figs. 5 and 6).
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Fig. 4. Treatment with E2 and TAM significantly decreased the 2-OHE1/16-OHE1
ratio compared with the treatment with E2 alone in Ishikawa cells; RAL increased
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Fig. 5. Treatment with TAM significantly decreased the 2-MeOE2/4-OHE1 ratio in
EM1  cells; treatment with RAL significantly increased this ratio. The ratio of 2ME/4-
OHE1 ratio in culture media from EM1  cells treated with E2 10 nM alone or with
various concentrations of TAM or RAL as previously described. *Significant (P < 0.05)
difference compared with treatment with E2 alone. Values represent the mean; bars
represent the standard error of the mean.
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Fig. 7. TAM significantly increased the levels of depurinating DNA adducts in EM1
cells. The levels of DNA adducts (4-OHE1 [2]-1-N7Guanine and 4-OHE1 [2]-1-N3
Adenine), were determined in culture media from EM-1 endometrial cells treated
with either E2 (10 nM)  alone or in combination with either TAM (1 M)  or RAL
(1  M) by ultraperformance liquid chromatography/tandem mass spectrometry
(UPLC–MS/MS).
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Fig. 8. TAM significantly increased the levels of depurinating DNA adducts in
Ishikawa cells. The levels of DNA adducts (4-OHE1 [2]-1-N7Guanine and 4-OHE1
[2]-1-N3 Adenine) were determined in culture media from Ishikawa endometrial
cells  treated with either E2 (10 nM)  alone or in combination with either TAM (1 M)
or  RAL (1 M)  by ultraperformance liquid chromatography/tandem mass spectrom-
etry (UPLC–MS/MS).
3.4. Effect of TAM or RAL on estrogen-induced depurinating DNA
adducts
To investigate the implications of the possible effects of TAM
or RAL on E2 metabolism and the formation of depurinating DNA
adducts, the levels of DNA adducts (4-OHE1 [2]-1-N7Guanine and
4-OHE1 [2]-1-N3 Adenine) were determined in culture media
from endometrial cells treated with either E2 (10 nM)  alone or
in combination with either TAM (1 M)  or RAL (1 M)  by ultra-
performance liquid chromatography/tandem mass spectrometry
(UPLC–MS/MS). Our results indicated that in EM1  and Ishikawa
cells, TAM significantly increased the levels of the depurinating
DNA adducts 4-OHE1 [2]-1-N7Guanine and 4-OHE1 [2]-1-N3 Ade-
nine compared with treatment with E2 alone. RAL (1 M)  did
not significantly change the level of E2-induced DNA adducts
(Figs. 7 and 8).
3.5. Effect of TAM or RAL on estrogen-metabolizing genes
expression in endometrial cells
To understand the underlying mechanism of the differential
pattern of estrogen metabolites and the rate of estrogen-induced
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Fig. 9. Expression of CYP1A1, CYP1B1, S-COMT, MB-COMT, NQO1, and -actin in
EM1 cells. Cells were treated with E2 alone or in combination with various concen-
trations of TAM or RAL. Total cell lysates, nuclear fraction, and cytoplasmic fraction
were  prepared as described in Section 2. CYP1A1, CYP1B1, S-COMT, MB-COMT,
NQO1, and -actin expression were determined using Western blot analysis. The
level of CYP1B1 was increased by E2 and further increased by addition of TAM. The
expression of CYP1A1 was decreased by E2 and further decreased by addition of
TAM. E2 alone or in combination with TAM resulted in a marked reduction in COMT
and NQO1 expression compared with the control.
adducts formation between TAM- and RAL-treated endometrial
cells, we assessed the effect of TAM or RAL on the expression of
key genes involved in estrogen metabolism. We  studied the effect
of E2 with and without TAM or RAL on the expression of CYP1A1
and CYP1B1 in EM1. As indicated in Fig. 9, the expression of CYP1B1
was induced by treatment with E2. The level of CYP1B1 was  fur-
ther increased by TAM (Fig. 9). In contrast to TAM, RAL did not
affect the CYP1B1 expression in EM1. Regarding the CYP1A1 pro-
tein expression, our data suggest that E2 downregulated CYP1A1
expression compared with vehicle-treated control. The downregu-
lation of CYP1A1 was even more pronounced by co-treatment with
TAM. In contrast, RAL notably increased the CYP1A1 expression in
EM1  cells (Fig. 9).
In extrahepatic tissues, including endometrial tissues, the cate-
chol estrogens are detoxified primarily by O-methylation catalyzed
by catechol-O-methyltransferase (COMT) and NAD(P)H-quinone
oxidoreductase (NQO1). These detoxification reactions impede the
easy oxidation of catechol estrogens to corresponding genotoxic
metabolites and prevent the formation of estrogen depurinating
DNA adducts. Accordingly, we also investigated the expression of
COMT and NQO1 enzymes in endometrial cells treated with E2
alone or in combination with TAM or RAL. Our data revealed that E2
alone or in combination with TAM resulted in a marked reduction
in COMT and NQO1 expression compared with the vehicle-treated
control. The reduction in COMT and NQO1 expression was  more evi-
dent in cells treated with E2 and TAM compared with cells treated
with E2 alone. On the other hand, in E2 plus RAL-treated cells,
there was a slight increase in COMT and NQO1 expression com-
pared with cells treated with E2 alone (Fig. 9). A similar profile of
Fig. 10. Expression of SF-1 and GAPDH in EM1  cells and Ishikawa cells. Cells were
treated with E2 alone or in combination with various concentrations of TAM or
RAL. Total cell lysates, nuclear fraction, and cytoplasmic fraction were prepared as
described in the materials and methods section. SF-1 and GAPDH expression was
determined using Western blot analysis. The level of SF-1 was  increased by addition
of  TAM in EM1  and Ishikawa cells.
estrogen-metabolizing gene expression was observed in Ishikawa
cells.
GPR30 estrogen receptor (GPER) has been shown to activate the
steroidogenic factor 1 (SF-1), which is a transcription factor that
induces aromatase expression in endometrial cells. Therefore, we
investigated the effect of TAM and RAL on the expression of SF-1
in EM1  and Ishikawa cells. Our results show that TAM induced the
expression of SF-1 in both EM1  and Ishikawa cells (Fig. 10).
4. Discussion
Although, both TAM and RAL are members of the SERM class
of drugs, they have distinctive effects on endometrium, and the
underlying mechanisms of their disparate effects are not fully
understood. Understanding of the relevant pathways involved in
TAM-associated EC is a matter of great importance to allow more
accurate assessment of the risk to women receiving TAM treatment
and, more importantly, to develop chemoprevention approaches. It
is postulated that TAM-associated EC is attributed to the hormonal
effect of TAM on endometrial tissues and its potential to form DNA
adducts [6–8,5].  However, this mechanism has been disputed, and
many studies even suggest that initiation of EC by TAM does not
involve the formation of TAM-DNA adducts [15,14,13].  This is con-
sistent with the finding that TAM-DNA adducts cannot be detected
in endometrial DNA from women who had undergone TAM therapy
for extended period of time, even with the use of specific detection
techniques, such as HPLC–electrospray ionization-tandem mass
spectrometry (HPLC–ES-MS/MS) [17,15,14,13,16]. Although, TAM-
adduct formation may  occur at a very low level in a proportion
of patients, the significance of TAM-DNA adducts in the devel-
opment of EC is unclear. These mixed results and the apparent
inconsistencies of the data regarding TAM-DNA adducts in human
endometrial tissues suggest that there may  be an alternative or
complementary mechanism underlying TAM-induced EC. Increas-
ing experimental evidence suggests that TAM-induced EC may
proceed as a consequence of TAM-induced changes in gene expres-
sion in endometrial epithelial cells [32,33]. Indeed, substantial
evidence suggests a potential role for TAM in regulating the expres-
sion of genes involved in estrogen biosynthesis and metabolism
[25,22–24,26,27]. Thus, this explains our novel approach aimed at
investigating the hypothesis that TAM induces EC by altering the
rate and pattern of estrogen metabolism/metabolites (EM). In addi-
tion, the disparate effects of TAM and RAL in EC risk are attributed,
at least in part, to their differential effects on estrogen metabolism.
It is widely believed that estrogen-induced cancers are
attributed, at least in part, to certain estrogen metabolites, which
have profound consequences on the biological, as well as the patho-
logical, effects of estrogen. Indeed, there is evidence that in situ
formation of estrogen metabolites can have biological properties,
even at very low concentrations, which can exceed the effects
of their parent substance by many fold [34,35].  It has been sug-
gested that many of the effects of estrogen may not be caused
by estradiol per se but may  result from the formation of active
estrogen metabolites that function as local mediators or activate
their own  unique receptors or effectors [36]. 17-Estradiol (E2)
is metabolized into a variety of compounds that are different in
their hormonal and carcinogenic potentials. 4-hydroxyestradiol
and 16-hydroxyestrone are tumor promoting, whereas the 2-
hydroxylation pathway demonstrates weak estrogenic or even
antiestrogenic effects [37,36]. In addition, 2-methoxyestradiol
(2-MeOE2) is an anticancer and antiangiogenic agent [38]. We  pre-
viously demonstrated that E2 and 4-hydroxyestradiol (4-OHE2)
induce oxidative stress, microsatellite instabilities, and neoplas-
tic transformation of human endometrial glandular epithelial cells,
whereas 2-hydroxyestradiol (2-OHE2) does not cause cellular
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transformation or genomic instabilities [21]. Thus, the imbalanced
expression of estrogen-metabolizing genes, the profile of estrogen
metabolites, and the predisposition of the individual metabolite
pattern might be crucial for many physiological and pathological
conditions in the endometrium.
One of the interesting findings in our study is that the total EM
was significantly higher in conditioned media from endometrial
cells treated with E2 plus TAM compared with cells treated with E2
alone. By contrast, RAL treatment did not result in any significant
change in EM.  Of note, the stability of estrogen metabolites detected
in this manner has been verified in a separate study [39]. This TAM-
associated increase in total EM could suggest that TAM increased
the local estrogen biosynthesis in endometrial cells. TAM-induced
increase in total EM could be explained in light of the finding that
TAM stimulates the GPR30 estrogen receptor (GPER), which in turn,
activates the steroidogenic factor 1 (SF-1), which is a transcrip-
tion factor that induces aromatase expression in endometrial cells
[40–42,22].
The interconversion of weakly active estrone (E1) into highly
potent estradiol (E2) and their relative abundance dictate the estro-
genic milieu. A decrease in the E1/E2 ratio is conducive for the
development of EC. Our results suggest that TAM significantly
decreased the E1/E2 ratio due to a decrease in the disposition
of estrogen as E1 with a concomitant increase in E2 concentra-
tion. This alteration in E1/E2 ratio could be explained in light of
the experimental evidence that TAM modulates the expression of
hydroxysteroid (17beta) dehydrogenase 1 (HSD17B1), an enzyme
that efficiently catalyzes the conversion of E1 into E2 [23,43,44].
Another important finding in our study is that, in contrast to RAL,
TAM alters the 2- and the 16-hydroxylation pathways of estrogen
metabolism in endometrial cells, which results in TAM decreasing
the 2-OHE1/16-OHE1 ratio. The 16-OHE1 metabolite is a potent
estrogenic molecule that activates estrogen receptors, whereas the
2-OHE1 metabolite has very little estrogen receptor binding affinity
(<0.1% compared to E2) [45]. Observational trials have demon-
strated that a decreased ratio of 2- to 16-alpha-hydroxyoestrone
is associated with EC risk [46]. Thus, it is anticipated that fac-
tors, which decrease the 2-OHE1/16-OHE1 ratio, such as TAM,
could induce EC. On the other hand, RAL, which exerts a modest
increase in 2-OHE1/16-OHE1 ratio, does not increase, and, in fact,
decreases the risk for EC [4].  Also, our data indicate that treatment
with TAM is associated with increased levels of 4-OHE1, one of the
most potent carcinogenic estrogen metabolites [47]. Interestingly,
this is accompanied by a significant decrease in the anticarcino-
genic estrogen metabolite 2-methoxyestradiol. Thus, it would be
anticipated that the collective effect of TAM on EM can enhance
the estrogenic milieu and create a metabolic microenvironment
conducive for the development of EC. This profile of estrogen
metabolites is a result of imbalances in the relative expression of
critical enzymes involved in estrogen activation/deactivation in the
endometrial EC.
We  then investigated the biological consequences of the TAM-
or RAL-derived estrogen metabolism/metabolites by measuring the
formation of estrogen-DNA adducts. In addition to its estrogenic
activity on cell proliferation, 4-OH-E2 undergoes redox cycling
during which reactive oxygen species, such as superoxide anion
and the chemically reactive estrogen semiquinone and quinone
intermediates, are produced. These genotoxic estrogen metabo-
lites react with DNA to form depurinating DNA-adducts. Indeed, our
study demonstrated that treatment with TAM is associated with a
significant increase in estrogen-induced depurinating adducts. It is
likely that the increase in estrogen-depurinating adducts resulted
from the increased level of 4-OHE1 and downregulation of the
detoxification enzymes COMT and NQO1. Depurinating adducts
can induce mutations and genomic instabilities in critical genes
such as the K-ras oncogene and tumor suppressor genes TP53 and
PTEN. These events can cause phenotypical changes indicative of
neoplastic transformation in endometrial tissues [21].
To understand why TAM or RAL alters the rate and pattern of
estrogen metabolites, we explored the effect of TAM or RAL on the
expression of key genes involved in estrogen metabolism. Our data
indicate that TAM increases the expression level of CYP1B1, while it
decreases CYP1A1 expression. In contrast to TAM, RAL did not affect
CYP1B1 expression but notably increases CYP1A1 expression. These
effects were associated with a concomitant effect on the expres-
sion of detoxification enzymes COMT and NQO1. TAM reduces
COMT and NQO1 expression while RAL causes a slight increase
in COMT and NQO1 expression. In previous studies, it was shown
that CYP1A1 and CYP1B1 gene expression, which are responsible
for the metabolism of estrogen into 2-OHE1 and 4-OHE1, respec-
tively, can be regulated by estrogen receptors, which are activated
by TAM or RAL in endometrial cells [38,48]. Similarly, CYP3A4,
which is responsible for the oxidation of estrogen into 16-OHE1,
is induced by TAM [49,50]. Similarly, several reports point to
the ability of SERMs to modulate the expression of the estrogen-
detoxification enzymes [25,51]. The observation that TAM and RAL
differentially regulate the expression of genes involved in estrogen
metabolism is consistent with previous studies showing differ-
ences of TAM and RAL on gene expression [52]. These differences
can be explained based on the mounting evidence that TAM and
RAL have different affinities for different subtypes of estrogen
receptors. Furthermore, different ligand–receptor complexes are
capable of regulating gene expression through different coregu-
lator recruitment in a gene-specific manner [32,53]. In addition,
previous studies have demonstrated that the transcriptional activ-
ity of TAM is mediated by its interaction with target gene promoters
that harbor either a classical ERE, a half ERE site, or EpRE [54,55].
Thus, it is reasonable to speculate that owing to their different
conformations, different coactivator associations, and differential
affinity to other receptors, TAM and RAL possess different affinities
for different gene promoters that would explain differences in gene
regulation, including estrogen metabolizing genes.
5. Conclusion
Our novel data suggest a new potential mechanism for
TAM-associated EC and provide a plausible explanation for the dif-
ferential effects of TAM and RAL on EC risk. Our study suggests that
TAM-induced imbalanced expression of estrogen-metabolizing
enzymes and altered disposition of estrogen metabolites can
explain, at least in part, the mechanism for TAM-induced EC. TAM
and RAL have different effects on the expression of E2 metabolizing
genes, estrogen metabolites, and on estrogen-DNA adduct forma-
tion, which may  play a role in their different risk profiles for EC.
However, our results do not exclude the possibility that other as-
yet-undetermined factors may  contribute to the differential effect
of TAM and RAL on the endometrium as well as the carcinogenic
effect of TAM.
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